Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Association of blinatumomab treatment with myelosuppression was examined in this study. Peripheral blood counts were assessed prior to, during, and after blinatumomab treatment in patients with relapsed/refractory Philadelphia chromosome-negative (Ph−) B-cell precursor (BCP) acute lymphoblastic leuk...
Enregistré dans:
Auteurs principaux: | Hagop M. Kantarjian, Gerhard Zugmaier, Monika Brüggemann, Brent L. Wood, Heinz A. Horst, Yi Zeng, Giovanni Martinelli |
---|---|
Format: | article |
Langue: | EN |
Publié: |
MDPI AG
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/c231d049e90a4489be5d68650cd3c8ec |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy
par: Franquiz MJ, et autres
Publié: (2020) -
Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy
par: Sigmund AM, et autres
Publié: (2020) -
Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
par: Fatih M. Uckun, et autres
Publié: (2021) -
Profound leukemia cutis in a patient with relapsed T-cell acute lymphoblastic leukemia
par: Ambika Nohria, BA, et autres
Publié: (2021) -
Other (Non-CNS/Testicular) Extramedullary Localizations of Childhood Relapsed Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma—A Report from the ALL-REZ Study Group
par: Andrej Lissat, et autres
Publié: (2021)